YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Pfizer may merge off-patent drug business with Mylan

Posted online

Pfizer Inc. is considering a merger of its off-patent drug business with generic drugmaker Mylan, people familiar with the matter told The Wall Street Journal.

Under the proposal, Mylan shareholders would own more than 40% of the new entity and Pfizer shareholders would own the remainder.

Such a deal would create a global company that sells lower-priced pharmaceuticals.

Read more from The Wall Street Journal.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Open for Business: BluCurrent Credit Union

BluCurrent Credit Union held a June 21 grand opening at an office building it renovated at 4520 S. National Ave.; Ozark Mountain Gymnastics changed ownership; and a Branson theater property made way for a new entertainment business with the opening of Star Concert Hall.

Most Read
Update cookies preferences